Efficacy of the Cordia myxa Syrup (Sepestan) on Reduction of Severity and Duration of Diarrhea in Pediatrics with Gastroenteritis: A Randomized Placebo-Controlled Trial
Abstract
Background: Diarrhea is one of the most common gastrointestinal problems in children, potentially leading to dehydration, weakness, and hospitalization. Various treatments have been proposed to reduce the severity and duration of diarrhea; however, the need for more effective approaches remains. Objectives: This study aimed to evaluate the efficacy of Cordia myxa syrup, known as “Sepestan,” in reducing the severity and duration of diarrhea in patients with gastroenteritis. Methods: This double-blinded, randomized controlled clinical trial was conducted using the simple randomization method. A total of 140 patients with gastroenteritis aged 1 - 8 years, referred to Abuzar Hospital in Ahvaz, Iran in 2024, were enrolled. Patients with gastroenteritis whose symptoms had occurred within less than 24 hours, with no prior medication use, no severe dehydration, and no abnormal stool findings were included. These eligible patients were divided into two equal groups: The intervention group (receiving C. myxa syrup) at a dose of 20 mg/kg/day, and the control group (receiving placebo). Data on age, sex, diarrhea severity and frequency, stool volume and consistency, duration of diarrhea, and other clinical symptoms were recorded and analyzed on days 1, 2, 3, and 7. Both the patients (and their parents) and the researchers were blinded to the assigned treatment groups. Results: The mean age of participants was 27.53 ± 18.81 months. The C. myxa group demonstrated a statistically…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 140 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.